Archive for the 'Hepatitis C' Category

Milk Thistle Extract and Its Effect on Liver Fibrosis

Thursday, April 20th, 2006

Silybin Phytosome® to Prevent Fibrosis
April 10, 2006
Liversupport.com
Nicole Cutler, L.Ac.

Regardless of its cause, the progression of liver disease is typically measured by the suppleness, and in turn, the functionality of the liver. Recent studies demonstrate the ability of the milk thistle extract, Silybin Phytosome®, to inhibit the hardening of liver tissue.

Some types of liver disease respond well to prescribed therapy, while others take on a chronic status. In addition to addressing the underlying cause of dysfunction, these chronic liver diseases require vigilance to support liver tissue health. While each disease has a preferred conventional treatment standard, an increasing number of clinicians are predominantly concerned with fibrosis prevention.

According to the Merck Manual, Fibrosis is an accumulation of fibrous tissue in the liver resulting from an imbalance between production and degradation of the extracellular matrix, and accentuated by the collapse and condensation of preexisting fibers. In more general terms, fibrosis is the hardening of liver tissue, occurring when the liver is impaired and thus, unable to break down fibrous material.

The liver is touted as the most dynamic organ in the body. This title is not only a result of the numerous functions for which it is responsible, but also for its self-restorative capability. The liver is the only organ capable of regenerating parts of itself to repair any sustained damage.

Helping maintain the liver’s texture is akin to supporting this organ’s health. To prevent or inhibit fibrosis, all individuals with liver disease would benefit from an accelerated regeneration of damaged liver tissue.

In Europe, silymarin, the purified extract of the fruits of S. marianum, and its main constituent, silybin, are used to maintain liver health. Worldwide, milk thistle is, deservedly, one of the most commonly prescribed medicinal plants.

S. marianum is a medicinal plant which has been widely used in traditional European medicine for centuries. Commonly known as milk thistle, St. Mary’s thistle and lady’s thistle, it is native to southern Europe, southern Russia, Asia Minor and North Africa. It has been naturalized to North and South America.

Literally hundreds of research studies, mostly conducted in Europe, have confirmed the remarkable ability of milk thistle to protect the liver against virtually all types of damage: from accidental exposure to chemical pollutants, toxic side effects of medications and even the self-inflicted damage from overindulgence of rich food and alcohol.

The United States National Library of Medicine has catalogued more than 300 scientific studies of milk thistle and its active compounds in their medicine database.

The active ingredients of milk thistle are not very bioavailable, especially in their purified or standardized forms. This means one would need to ingest large amounts to experience beneficial effects. Not only impractical, it could be quite expensive.

A recent study published in Digestive and Liver Disease, clearly demonstrates the ability of Silybin Phytosome® to inhibit liver fibrosis. This study confirmed Silybin Phytosome’s® hepatoprotective abilities by proving it counteracts the progression of liver fibrosis typically seen in chronic liver diseases.

On a molecular level, fibrosis is marked by excessive accumulation of extracellular matrix with collagen. The hepatic stellate cells activate this cumulus. In the referenced study, Silybin Phytosome® reduced hepatic stellate cell activation and proliferation. It also significantly reduced the synthesis and deposition of collagen in liver tissue. The authors of this study concluded that Silybin Phytosome® could inhibit liver fibrosis by reducing the synthesis of collagen and by interfering with excessive accumulation of extracellular material.

Additional evidence of silybin’s value in preventing fibrosis is garnered from a 1984 study demonstrating that silybin accelerates the rate of protein synthesis in the liver, leading to faster cell regeneration. A 1997 German study also reported results where silybin reduced the proliferation of hepatic stellate cells by 50 to 75 percent, which again, is highly indicative of its anti-fibrotic effect.

By their very nature, chronic liver diseases are persistent and stubborn to known modern treatments. Chronic liver disease summons our attention to provide every bit of hepatic support possible, until our medical expertise can catch up with us and ameliorate the offending disease. Years of research point to the ability of Silybin Phytosome® to meet this demand, by preventing the damage that liver diseases typically cause.

For more information on supplements containing Silybin Phytosome®, visit LiverSupport.com.

A New Study on HIV/HCV Co-Infection and Race

Thursday, April 20th, 2006

Whites fare poorly with HIV and hepatitis C

Will Boggs, MD
Reuters
April 18, 2006

NEW YORK (Reuters Health) - Liver disease and death rates are worse with hepatitis C virus (HCV) infection on top of HIV infection than with just HIV or HCV, especially among white patients, according to a new report.

“We need to better understand why the co-infected patients do so poorly and the underlying mechanism for apparent racial disparity in their outcome,” Dr. Kyong-Mi Chang, told Reuters Health.
“We also need better drugs that directly target HCV,” added Chang, from the University of Pennsylvania and Philadelphia Veterans Affairs Medical Center.

Chang’s team examined the impact of dual infection and race in 265 veterans with HCV/HIV co-infection, 251 infected with HCV only, and 227 others with HIV only.

Over a three-year period, mortality was significantly greater among HCV/HIV-co-infected patients than among patients mono-infected with either HCV or HIV, the researchers report in the American Journal of Gastroenterology.

Specifically, after taking into account a variety of factors, mono-infected patients were only about one-third as likely to die as dual-infected patients.

During the study period, twice as many white patients died compared to black patients, the report indicates.

Also, the average age at death in white patients (46 years) was significantly younger than that in black patients (52 years).

Since dual-infected patients fare so poorly, Chang said, the team aims to treat them “as much as possible and monitor them closely for liver dysfunction.” He said specialists in liver disease and infectious diseases “as well as pharmacists (also social work and mental health support), is needed to optimize therapy for these complex patients.”

SOURCE: American Journal of Gastroenterology, April 2006.

Your Liver, Springtime and Traditional Chinese Medicine

Thursday, April 20th, 2006

by Nicole Cutler, L.Ac.

During the winter, we withdraw from the world to reflect, rejuvenate and rest. When the season shifts into spring, energy bursts forth, like bulbs long dormant in the colder months. As daylight lengthens, the inwardly contained energy begins to flow instead of being stored. Nature’s flurry of activity associated with spring is found everywhere, from newly composed avian harmonies to animal mating rituals. Projects sitting on hold jump to life and bodies that have been curled up on the couch itch to move. Spring is representative of transformation and growth, bringing renewed optimism, hope and life.

According to Chinese culture, humans are microcosms of the environment, and are equally affected by the change in season. The cyclical character of energy flow creates a predominance of energy in each body system during a particular season. According to Chinese medical theory, the liver and gallbladder systems are partners, and their energy is most active in the spring. It is logical then, that for individuals living with liver disease, Chinese medical practitioners put extra emphasis on initiating change after the vernal equinox.

Other holistic practitioners also recognize this time of year as pertinent to liver health. Nutritionists typically target spring as ideal for a liver flush, or liver cleanse. Eating vegetables that grow in the spring are recommended by dieticians to aid in moving winter’s sludge out of the liver. No matter what angle taken, the liver is most accessible for transformation during this season.

In addition to viewing humans as a mirror of nature, Chinese medical theory emphasizes the interplay of physical, emotional and spiritual aspects governed by each body system. Encompassing much more than the western medical model’s understanding of organ structure and function, each body system also governs emotion, cognition and spirit.

The cognitive responsibility of the liver is planning and the gallbladder oversees decision-making. When the energy in these two organ systems mounts, as it naturally does each spring, there can be two possible outcomes:

· The desired outcome is an active outpouring of creativity, productivity and release of negative patterns.
· The undesired outcome is energetic stagnation, or resistance to allowing this energy to flow.

Restricted liver energy manifests as anger, frustration, depression and irritability. Liver disease occurs or worsens when this restriction is not expressed or freed. When energy remains stuck, it coagulates, which hampers optimal body functioning. In nature, this is just like a heavy storm’s debris clogging a creek’s thoroughfare, preventing water flow downstream of the obstruction. If the obstruction is not cleared, more debris will accumulate, further preventing the creek’s inclination to flow. The inability to express spring’s active energy can lead to all sorts of illnesses including migraines, cystic breasts, digestive problems and even a progression of liver disease.

Because the energy in the liver and gallbladder systems increase in the spring, people often experience an increase in stress, anger and anxiety during this season. When an outlet for this energy is found, these emotions can be transformed into creativity, opportunity and change. Springtime is ideal to convert these difficult emotions through focusing on their movement and release. Nature provides us with this perfect time of year to spring clean our emotional accumulation. Feeling these intense emotions is the healthy first step, and indicates readiness, or near-readiness for the second spring cleaning step: release.

Emotional release can be achieved in many different ways, and each person needs to find the method that works best for them. Some methods that may be useful include:

· Engaging in physical activity
· Receiving bodywork
· Verbalizing emotions to a friend or professional
· Journaling or writing about one’s feelings
· Crying and/or laughing
· Meditation and/or visualization
· Using creativity as an emotional outlet

Regardless of the method used, finding the path to emotional release keeps the body, mind and spirit healthy. The natural instinct to spring clean our homes and environment answers our yearning to clear away the cobwebs (stagnation) left over from winter. When spring cleaning is applied to emotional health, our ability to plan and make decisions blossoms and we experience renewed optimism, creativity, hope and transformation.

From the Chinese perspective, the free flow of liver and gallbladder energy is the number one disease preventative, and the best way to guarantee health and happiness. Take advantage of spring’s manifestation in your body, and for liver’s sake, decide to do some emotional spring cleaning.

Influencing Liver Disease with Diet

Thursday, April 20th, 2006

by Nicole Cutler, L.Ac

Everything we eat, breathe and otherwise absorb is processed by the liver. By purifying and transforming our food into substances fueling our body, the liver is dependant on what we feed ourselves. In the face of liver disease, where liver function is impaired, proper nutrition takes on increasing importance. A balanced diet containing sufficient calories and an appropriate ratio of carbohydrates, proteins and fats can assist a damaged or struggling liver to regenerate new, healthy liver cells.The common liver disease, cirrhosis, refers to the replacement of damaged liver cells by fibrous scar tissue. Fibrous scar tissue inhibits the liver from performing its many varied, critical functions. Individuals with cirrhosis typically experience weight loss, which is associated with either a decreased intake of food, or a decreased ability to process food.

Protein and the Liver

Protein in our diet comes from foods such as meat, fish, eggs, cheese, nuts and dairy. Proteins typically provide the building blocks for the body to repair damaged tissue. However, in the case of a severely damaged liver, ingested proteins may not be properly processed, leaving excessive toxic waste circulating in the body. With any type of liver disease, it is paramount to work closely with a healthcare physician to design a customized nutritional plan.

According to the American Liver Foundation, adults with cirrhosis require a balanced diet rich in protein, allowing liver cells to regenerate. However, too much protein can have the opposite effect. According to Melissa Palmer, MD, author of Dr. Melissa Palmer’s Guide to Hepatitis and Liver Disease, “If too much protein is consumed and not enough carbohydrates, the liver will be forced to use protein as an energy source. This is an unwise and inefficient use of protein, as protein will be diverted from its primary job of building cells and tissues. Furthermore, this will put undo stress on the liver, as it is more taxing for the liver to convert protein into energy than it is to convert carbohydrates into energy.”

The Atkins diet is a popular weight-loss plan encouraging consumption of very high amounts of protein and very low amounts of carbohydrates. Critics of the Atkins diet emphasize the danger that a diet centered on protein can have on the body. High protein intake can change the pH of the blood, making it very acidic. When the blood is too acidic, the body goes into a state of ketosis, a life-threatening metabolic condition that can seriously damage the liver. Because of the possible repercussions, a knowledgeable physician must determine the amount of protein consumed by someone with impaired liver function. Whether concerned with helping the liver regenerate healthy cells, or preventing the dangerous condition of ketosis, those with liver disease should not leave their protein consumption to chance.

Carbohydrates and the Liver

Carbohydrates come from starch and sugar and are found in food such as bread, potatoes, rice, pasta, cereals, fruit and sweets.The body breaks down carbohydrates into glucose, and stores it in the liver as glycogen. Glycogen is essential for a steady supply of energy, as it is released between meals when blood sugar levels drop. Therefore, glycogen is the link connecting the liver with blood sugar regulation. According to Palmer, “People with liver disease should strive for a diet consisting of approximately 60 to 70 percent carbohydrates, with complex carbohydrates predominating. For such people, a well-balanced diet will include at least 400 grams of carbohydrates.” Most experts agree that for optimal nutritional value, carbohydrates should be the main source of calories for individuals with liver disease.

Fats and the Liver

Fats in our diet come from many sources including butter, lard, cream, cooking oils, cheese, animal fats and many prepared foods.According to Palmer, “Ideally, a person should aim for something in the neighborhood of 10 to 20 percent. People who are overweight should aim for 10 percent. While it is important to eat as little fat as possible, eating a small amount of the more healthy fats does have some benefit … essential fatty acids, perform (as the name suggests) a variety of duties that are essential to the proper functioning of the body.”Some people with liver disease have problems digesting and absorbing fat. Individuals with this issue likely need to decrease their fat intake and will be instructed by their physician to consume a certain type of fat more easily absorbed by the body.

Conclusion

Although liver disease is so prevalent in today’s society, most people are unaware of how influential food can be to our liver’s health. While most authorities agree that carbohydrates should be the most predominant part of a liver supportive diet, balanced amounts of protein and fat are also crucial. Choosing the right balance of foods with your physician will take your specific metabolism needs and liver health status into consideration. When individuals with liver disease follow their advised nutritional program, the support offered to their liver is unmatched by any modern medical intervention.

References:

Ganong, William F., MD, Review of Medical Physiology, Prentice Hall, 1991.
Palmer, Melissa, MD, Dr. Melissa Palmer’s Guide to Hepatitis and Liver Disease, Penguin Putnam, 2004.
http://www.liverfoundation.org/, Diet and Your Liver, American Liver Foundation, 2003.
http://www.newsday.com/, Weighing the risks of Atkins diet, Delthia Ricks, 3/18/06.
http://www.nlm.nih.gov/, Diet – liver disease, Medline Plus, 9/22/05.

Replication Discovery Provides New Treatment Approach

Thursday, April 20th, 2006
April 5, 2006
Stanford Office of Communication and Public Affairs 

STANFORD, Calif. — Last year Peter Sarnow, PhD, professor of microbiology and immunology at the Stanford University School of Medicine, identified a previously unknown mechanism that the hepatitis C virus uses to replicate, yielding a promising new approach to combating the disease-causing virus. On April 5 at the Experimental Biology meeting in San Francisco, Sarnow will discuss recent developments in this work—including his partnership with two pharmaceutical companies that seeks to use the new understanding of the virus to develop treatments.

According to the World Health Organization, hepatitis C virus infects 170 million people worldwide. About 70 percent of those infected develop liver disease, including cirrhosis and liver cancer. In the United States, it is the most common blood-borne viral infection, killing more than 10,000 people each year. Currently available treatments are expensive and do not work in about half of the cases.

“Normally with an RNA virus like hepatitis C, resistance to antivirals very quickly emerges, so the drug is not effective any more,” said Sarnow, who has been studying the virus for years, sorting out how the viral RNA amplifies in cultured liver cells.

In the normal sequence of events, genetic information is stored in DNA and then is copied into RNA, which serves as a template to create proteins. With RNA viruses such as hepatitis C, the genetic information is stored in RNA instead of DNA.

RNA is genetically more unstable than DNA, resulting in the accumulation of many mutations. These mutations allow the virus to outwit the immune system and develop resistance to antiviral medication.

Sarnow’s group has shown that a small fragment of RNA found in the liver, known as a microRNA, is necessary for hepatitis C to grow and reproduce. Their work, published in September 2005 in the journal Science, is the first to link the presence of a specific microRNA with a major infectious disease.

When the researchers inactivated the microRNA, called miR-122, the amount of hepatitis C virus RNA was reduced by approximately 80 percent. “The cool thing is that here, an antiviral is encoded by a host function and not by the virus — so it cannot change,” said Sarnow. In other words, because the virus needs miR-122 to replicate, there is no way the virus could develop resistance to a strategy that inactivates miR-122.

A couple of years ago, Sarnow learned that other scientists had discovered miR-122, found only in the liver. He knew that there could be up to 65,000 copies of miR-122 per cell in the liver. “And we know that the virus can persist in the liver for as long as 30 years, so we made the hypothesis that the virus might interact with miR-122 in some way,” he said. “It turns out that yes, the virus grabs it for its own good.”

“This is a completely different way for microRNA to interact with its target from what is known and it brings up the idea that other microRNAs might work like that,” said Catherine Jopling, PhD, a postdoctoral researcher in Sarnow’s laboratory who spearheaded the work. “But nobody’s been looking for that.”

The researchers think that their findings may have therapeutic potential for a new antiviral target that does not attack the virus directly.

“If you can lower the amount of the microRNA in the liver without affecting liver function maybe this will help lower the viral load,” said Sarnow. Stanford has entered into a licensing agreement with Alnylam Pharmaceuticals and Isis Pharmaceuticals to explore the possibility of using miR-122 as a novel therapeutic against hepatitis C.

The big question is what does this microRNA normally does in the liver. It is possible that lowering microRNA levels in the liver might produce an undesirable outcome, such as cancer, said Sarnow. However, recent promising reports from researchers at Rockefeller University, Alnylam and Isis have demonstrated that miR-122 can be inactivated in mouse liver for some time without impairing liver function.

The Experimental Biology meeting is an annual gathering of groups covering a range of scientific disciplines, including anatomy, biochemistry, molecular biology, pharmacology and pathology. This year 12,000 scientists are expected to attend the event at the Moscone Center in San Francisco.

Ability to Culture Hepatitis C Virus Leads to Research Advancements

Thursday, April 20th, 2006
Researchers show laboratory hepatitis C strain is also infectious in animal models
27 March 2006
Rockefeller University Newswire 

An important step in developing a treatment for viral diseases is for scientists to culture live viruses from infected patients, but the hepatitis C virus (HCV), a major cause of chronic and sometimes fatal liver disease, has proven to be particularly wily. For many years scientists have struggled with an inability to efficiently culture HCV in the laboratory. Now, researchers at Rockefeller University have overcome several obstacles and successfully shown that a strain of HCV they created in the laboratory, which can efficiently be cultured in vitro, is also infectious in animals. The findings, reported in the March 7 issue of the Proceedings of the National Academy of Sciences, will enable scientists to study the life cycle of HCV at the molecular level and develop better treatments for this disease.

The researchers, led by Brett Lindenbach at Rockefeller and Philip Meuleman at Ghent University in Belgium, used a cell-culture version of HCV, developed by Lindenbach and colleagues at Rockefeller, called HCVcc. HCVcc, which was the first infectious cell-culture version of hepatitis C, was used to infect two chimpanzees as well as mice bearing human liver grafts. The researchers found that in both the chimpanzees and the mice, hepatitis C infection lasted for as long as 15 weeks. Also, the infections raised in the mice could be passed to other mice. Samples of the test tube-cultured strain could be recovered from infected animals and was easily recultured in vitro, unlike most other strains of HCV isolated from infected animals or people.

“The ability to study a genetically defined virus in the test tube and in living animals allows us to completely dissect the HCV life cycle,” says senior author Charles Rice, Maurice R. and Corinne P. Greenberg Professor and head of the Laboratory of Virology and Infectious Disease at Rockefeller.

The chimpanzees, which are housed at the Southwest National Primate Research Center in San Antonio, Texas, were previously used for studies of HIV and other strains of hepatitis, and were not infected with HCV before being inoculated with HCVcc. The mouse experiments, which took place at Ghent University, involved a strain of mice called uPA-SCID, which lack an immune system and mimic the liver failure that can accompany chronic hepatitis C infection in people.

In addition, the researchers found that the virus recovered from the experimentally infected animals had a higher infectivity than the original HCVcc. They also found that virus particles with a lower buoyant density — a measure of how well they float — had increased infectivity, suggesting that differences in the physical properties of the viruses grown in vitro and in vivo are important for biological activity.

These results show that it should be possible to culture HCV from clinical samples and provide a useful positive control to help isolate additional strains that grow in cell culture, Lindenbach and Rice say.

Herbal Components are Beneficial in Treating Cirrhosis

Thursday, April 20th, 2006

The efficacy of Liv.52 on liver cirrhotic patients: A randomized, double-blind, placebo-controlled first approach.
15 September 2005

Cirrhosis is the irreversible sequel of various disorders that damage liver cells permanently over time. Presently, the use of herbal medicines for prevention and control of chronic liver diseases is in the focus of attention for both the physicians and the patients; the reasons for such shift toward the use of herbals include the expensive cost of conventional drugs, adverse drug reactions, and their inefficacy. In the present study, the efficacy of herbal medicine Liv-52 (consisting of Mandur basma, Tamarix gallica and herbal extracts of Capparis spinosa, Cichorium intybus, Solanum nigrum, Terminalia arjuna and Achillea millefolium) on liver cirrhosis outcomes was compared with the placebo for 6 months in 36 cirrhotic patients referred to Tehran Hepatic Center. The outcome measures included child-pugh score, ascites, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), total billirubin, albumin, prothrombin time, platelet and white blood cells counts. The indices were recorded in all patients before and after 6 months of drug or placebo treatment. The results demonstrated that the patients treated with Liv-52 for 6 months had significantly better child-pugh score, decreased ascites, decreased serum ALT and AST. In placebo administered patients all the clinical parameters recorded at beginning of the study were not significantly different than after 6 months. We conclude that Liv-52 possess hepatoprotective effect in cirrhotic patients. This protective effect of Liv-52 can be attributed to the diuretic, anti-inflammatory, anti-oxidative, and immunomodulating properties of the component herbs.

More information about Liv.52 can be found at http://www.liversupport.com.

Abstract: “The efficacy of Liv.52 on liver cirrhotic patients: A randomized, double-blind, placebo-controlled first approach,” H. Fallah Huseini, S.M. Alavian, R. Heshmat, M.R. Heydari and K. Abolmaali, Phytomedicine; 12:9; September 2005 (DOI:10.1016/j.phymed.2004.10.003)

Rally for Hepatitis Awareness

Thursday, April 20th, 2006
Liver Organizations, Activist, Families & Support Groups Are Making Plans for May 2006, National Hepatitis C Awareness Month. 

Join the Hepatitis C Movement for Awareness during their fifth annual “Weekend for Awareness” beginning May 24, 2006 in Washington D.C. Promoting the need for a General Awareness campaign, HMA and other organizations will “March Across America.” Groups and individuals who cannot make the event in our nation’s capital are scheduling marches in their hometowns to rally local governments to inform citizens of the risk to their communities.

HEPATITIS C AWARENESS TO “MARCH ACROSS AMERICA”

Monday, March 6, 2006
Contact: HMA Press Office, 540-248-7324

WASHINGTON, DC– Hepatitis C Movement for Awareness (HMA) is once again hosting the Fifth Annual, “Weekend for Awareness,” with a new twist this year. Joining HMA, other groups and organizations will “March Across America,” promoting the need for a General Awareness Campaign.

In recognition of “Hepatitis C Awareness Month,” individuals and groups that can’t make the DC event, are scheduling a march in their own hometown. Most will rally on local government to inform about the risk to communities. Groups interested in participating can visit this link to sign up. The Movement provides pamphlets that volunteers can print out, which include a voucher for a free in home test kit.
http://www.march-on-dc.com/National/News/2006/LocalMarch.asp

Dubbed “The National Event,” held in DC, begins Wednesday, May 24. The first two days, local State teams will unite on Capital Hill, with scheduled appointments. This is followed by a “Kick Off” Rally and Silent Auction, Thursday evening. The March begins Friday, 10 AM, with plans to step off at 11:30. Participants will gather at Lafayette Park, across from the White House. There will be guest speakers from the Hepatitis C community. More information will follow.

Saturday is “National Testing Day”; a free day for enjoying the National Memorial activities. Services including parades and entertainment, Many volunteers will converge on the National Mall, distributing HMA’s pamphlets and vouchers. Events will end with a candlelight vigil that evening in memory of the 10,000 former Military Veterans that died last year because of Hepatitis C.

HEPATITIS C is viral infection of the blood, with almost 6 million Americans infected. It can lead to permanent problems, cirrhosis and organ failure. Only 20% know they have the infection. The only means to prevent it is through awareness, testing, and a “General Education Campaign.” There is no vaccine.

As the leading epidemic in the world and the number one cause of liver transplants in the United States, organizers want the message clear; “Our primary mission is to alert the public to the many ways the virus is spread while encouraging people to get tested.” Especially minorities and those with military backgrounds, most affected. Please come out and support a true effort for federal and state responses to this epidemic.

For more information and get a copy of the “Are You At Risk” pamphlet with a test kit voucher visit: http://www.march-on-dc.com/

A Breakthrough Discovery for Hepatitis C

Thursday, April 20th, 2006

Biologists at Florida State University have recently produced a study illuminating the replication and mutation of the Hepatitis C virus. This kind of progress represents a giant leap forward in tracking this persistent virus, which likely means more accurate and efficient therapy will be coming soon.

LANDMARK FSU STUDY OF HEPATITIS C VIRUS SOLVES MYSTERY THAT HAS STYMIED QUEST FOR CURE    

By Libby Fairhurst
February 7, 2006

TALLAHASSEE, Fla. –The hepatitis C virus (HCV) infects more than 170 million people worldwide and leads to both acute and chronic liver diseases. Since its discovery several decades ago, the insidious human pathogen has stymied the quest for anti-viral therapies by refusing to reproduce in test tubes for more than a few hours or days, denying scientists an efficient virus production and infection system for experimental research.

Now, in a landmark study by Florida State University biologists that could bolster the development of anti-viral therapies for HCV — as well as for related RNA viruses such as West Nile and influenza — Assistant Professor Hengli Tang and doctoral student/co-author Heather B. Nelson have discovered the molecular mechanism that inhibits HCV replication in vitro after its host cells become crowded and stopped dividing.

What’s more, their groundbreaking discovery came about as a result of the new test they developed that can quickly and easily monitor HCV replication in the laboratory. Finally, after Tang and Nelson uncovered the reason for suppression of the virus in cell culture — in a nutshell: not enough nucleotide molecules, the building blocks of HCV — they then adapted an existing cell technology to remedy the problem right in the test tube.

The Tang-Nelson study and a description of the innovative technologies they devised to enable and track it will appear in the Feb. 8 edition of the Journal of Virology.”Our findings could prove critical to research on HCV’s complex virus-host cell interactions and lead to better, targeted treatments,” Tang said. “Currently, any nucleotide starvation therapies, used primarily to treat cancer, can inhibit replication by depriving viral agents of their molecular building blocks. However, those therapies may impact healthy cells, as well, causing undesired side effects.”

In the human liver, the parasitic HCV makes copies of its genetic material by hijacking nucleotides — the little molecules produced by its dividing host cells. It is only in the liver that pools of nucleotides remain available to HCV in sufficient supply after the host cells reached confluence (stop dividing). Not so in test tubes, say the FSU researchers.

To address the shortage of HCV building blocks in vitro, their unique adaptation of an existing cell technology enabled the introduction of nucleoside molecules to a culture of liver cancer cells. The nucleosides then converted to the essential nucleotide molecules that Tang calls the missing link. In turn, the nucleotides generated in vitro replication of infectious HCV particles that continued even after host cell confluence — as it does in the liver.

That’s not all. “Our new cell line also allows us to rapidly identify and isolate drug-resistant HCV mutants in vitro and to screen for anti-viral drug candidates,” Tang said. “This will help researchers better study the mechanism of drug resistance, a big problem with this virus and others such as HIV (human immunodeficiency virus) that mutate quickly.”

Underpinning everything, Tang says, is their novel, easy-to-use assay. It can track mutant strains of HCV in a week or less while other assays take weeks or months.

“Our assay, for which FSU has filed a provisional patent application, employs a new reporter cell line, which means the cells give out a detectable signal when certain events happen inside them,” said Tang. “In this case, they emit a green fluorescence whenever HVC is replicating. The fluorescence is tracked in the cell culture through a technique known as flow cytometry, which employs a machine equipped with a laser and lights that follows the green to find the virus.”

Between earning his PhD at the University of California-San Diego in 1998 and joining FSU’s biological science faculty in 2004, Tang served as a lead researcher in an industry setting, seeking targeted anti-viral therapies primarily for HIV.

“I find it particularly rewarding to play a part in research that may actually help somebody soon,” he said.

The Tang-Nelson study at FSU — “Effect of Cell Growth on Hepatitis C Virus (HCV) Replication and a Mechanism of Cell Confluence-Based Inhibition of HCV RNA and Protein Expression” — was supported in part by a grant from the American Heart Association.

Vitamins Suggested During Combination Therapy

Thursday, April 20th, 2006

A Japanese research study demonstrates benefits of Vitamin E and C supplementation during combination therapy. These vitamins appear to protect cells from damage typically incurred from conventional Hepatitis C therapy.

Vitamins E and C May Aid Patients with Hepatitis C on Conventional Treatment  

In a study involving 30 patients with chronic hepatitis C who were receiving interferon-alpha-2b (IFN-alpha-2b) and ribavirin combination therapy, daily supplementation with vitamin E (500 mg/day) and vitamin C (750 mg/day) was found to improve the fatty acid composition of mononuclear cells. At baseline, all study subjects were found to have a lower level of EPA (eicosapentaenoic acid) and a higher level of the molar ratio of arachidonic acid to EPA in mononuclear cells, as well as a significant correlation between the molar ratio and the level of serum alanine aminotransferase, as compared with healthy volunteers. After intervention, subjects who did not receive nutritional supplementation (the “non-vitamin group” - 16 subjects) experienced a significant decrease in the EPA levels of mononuclear cells at 4 and 8 weeks into treatment, while subjects who received vitamins E and C daily (the “vitamin group” - 14 subjects) maintained the EPA level of mononuclear cells. Both groups experienced a significant decrease in serum levels of alanine aminotransferase two weeks into the treatment. In addition, the “vitamin group” was found to have increased levels of plasma and red blood cell alpha-tocopherol and plasma ascorbic acid levels. These results suggest that patients with hepatitis C who are undergoing IFN-alpha-2b and ribavirin therapy may benefit from supplementation with the antioxidant vitamins, E and C, through their effect on maintaining the level of EPA in mononuclear cell phospholipids. The authors hypothesize that the efficacy of IFN-alpha-2b and ribavirin therapy might be further improved through oral supplementation with EPA. Further research would be needed to test this hypothesis.

Reference
“Vitamin E and C supplementation prevents decrease of eicosapentaenoic acid in mononuclear cells in chronic hepatitis C patients during combination therapy of interferon alpha-2b and ribavirin,” Murakami Y, Nagai A, et al, Nutrition, 2006; 22(2): 114-22. (Address: Department of Nutritional Science, Faculty of Health and Welfare Science, Okayama Prefectual University, Okayama, Japan).